|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Galapagos_NV
gptkb:Yescarta
gptkb:Immunomedics
gptkb:Kite_Pharma
Foster City Pharmaceuticals
|
|
gptkbp:clinical_trial
|
gptkb:vaccine
HIV treatment
HCV treatment
|
|
gptkbp:employees
|
approximately 10,000
|
|
gptkbp:founded
|
gptkb:1987
|
|
gptkbp:founder
|
gptkb:Michael_L._Riordan
|
|
gptkbp:headquarters
|
gptkb:Foster_City,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
GILD
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:key_people
|
gptkb:Daniel_O'_Day
|
|
gptkbp:net_income
|
$5.5 billion (2020)
|
|
gptkbp:partnership
|
Gilead Sciences and Galapagos NV
Gilead and Bristol-Myers Squibb
Gilead and Merck
|
|
gptkbp:philanthropy
|
gptkb:Gilead_Foundation
Gilead's COVID-19 response
Gilead's HIV prevention programs
Gilead's community engagement initiatives
Gilead's support for healthcare workers
|
|
gptkbp:products
|
gptkb:Atripla
gptkb:Sovaldi
gptkb:Biktarvy
gptkb:Harvoni
Genvoya
|
|
gptkbp:research_focus
|
gptkb:virus
gptkb:Oncology
gptkb:HIV/_AIDS
Cell therapy
Inflammation
|
|
gptkbp:revenue
|
$24.7 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
gptkb:GILD
|
|
gptkbp:subsidiary
|
gptkb:Gilead_Sciences,_Inc.
Gilead Sciences Canada, Inc.
Gilead Sciences Ireland UC
Gilead Sciences Singapore Pte. Ltd.
Gilead Sciences Australia Pty Ltd.
Gilead Sciences Gmb H
|
|
gptkbp:website
|
www.gilead.com
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
|
|
gptkbp:bfsLayer
|
4
|